Form 4: STAAR Surgical Director Silverman Acquires 2,440 Stock Options

Director Louis Silverman acquired 2,440 stock options in STAAR Surgical Co. on May 12, 2025, according to a Form 4 filing.

Summary

• On May 12, 2025, Louis Silverman, a director of STAAR Surgical Co., acquired 2,440 common stock options at a price of $20.27.
• These options were granted pursuant to the corporation's standard non-employee director equity compensation program.
• The options vest fully on June 18, 2025, which is the date of the Corporation's 2025 Annual Meeting of Shareholders.
• Following the transaction, Silverman directly owns 2,440 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction related to director compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to director compensation and aligns with standard practices for publicly traded companies. It provides transparency regarding the equity-based compensation of company directors.

Comparison to Industry Standards

• Director compensation packages, including stock options, are common across publicly traded companies to align the interests of directors with those of shareholders.
• The vesting schedule and terms of these options are typical for director equity compensation programs.
• Comparable companies in the medical device industry, such as Alcon or Johnson & Johnson's vision care division, also utilize stock options as part of their director compensation.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with shareholder value.

Key Dates

Keywords

STAAR Surgical, Director, Stock Options, Form 4, Equity Compensation, Silverman, Acquisition